Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716834 | 0.87 | ALDH1A1 (0.56) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6713812 | 0.87 | ALDH1A1 (0.56) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6723832 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6717195 | 0.85 | MAPT (0.54) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6717494 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6715742 | 0.85 | NPC1 (0.56) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6717232 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6718586 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6717381 | 0.84 | ALDH1A1 (0.57) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6717122 | 0.84 | MAPT (0.50) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | SMN1; SMN2 1805/4885KMT2A 2020/4885MEN1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.